Neuberger Berman Group LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 864,473 shares of the healthcare product maker’s stock after buying an additional 20,660 shares during the period. Neuberger Berman Group LLC’s holdings in Abbott Laboratories were worth $42,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Sanders Morris Harris LLC lifted its position in shares of Abbott Laboratories by 0.3% during the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after buying an additional 16 shares in the last quarter. St. Louis Trust Co lifted its position in shares of Abbott Laboratories by 0.4% during the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after buying an additional 20 shares in the last quarter. Alpha Windward LLC lifted its position in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock valued at $264,000 after buying an additional 30 shares in the last quarter. Lakeview Capital Partners LLC lifted its position in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after buying an additional 33 shares in the last quarter. Finally, Johanson Financial Advisors Inc. lifted its position in shares of Abbott Laboratories by 0.5% during the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 70.64% of the company’s stock.

Shares of Abbott Laboratories (ABT) opened at $55.30 on Tuesday. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $95,384.93, a PE ratio of 22.74, a P/E/G ratio of 2.05 and a beta of 1.06. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $56.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period last year, the company earned $0.59 EPS. analysts predict that Abbott Laboratories will post 2.5 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s payout ratio is 83.47%.

In related news, insider Stephen R. Fussell sold 196,550 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at approximately $10,963,656. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $51.97, for a total value of $2,738,819.00. Following the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. Insiders have sold a total of 408,313 shares of company stock valued at $21,205,356 over the last three months. Corporate insiders own 0.76% of the company’s stock.

WARNING: “Abbott Laboratories (ABT) Stake Lifted by Neuberger Berman Group LLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/abbott-laboratories-abt-stake-lifted-by-neuberger-berman-group-llc/1701576.html.

ABT has been the topic of a number of research reports. Stifel Nicolaus restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a report on Friday, July 21st. Barclays PLC restated an “overweight” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a report on Saturday, July 22nd. BidaskClub lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $58.00 price objective on shares of Abbott Laboratories in a report on Thursday, August 3rd. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Abbott Laboratories currently has an average rating of “Buy” and an average target price of $56.81.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.